All investigators conducting a research study through the TraCS Institute have a responsibility to report problems or adverse events that occur during the research to the IRB (OHRE).

Adverse Event Reporting

All investigators conducting a research study through the TraCS Institute have a responsibility to report problems or adverse events that occur during the research to the IRB (OHRE).

See the OHRE reporting policy for Adverse Events and Unanticipated Problems.

Definitions

  • "Adverse event" or "adverse experience" (AE) is an undesirable and unintended, though not necessarily unanticipated, injury or physical or emotional consequence to a human subject.
  • "Unanticipated Problems" (UPs) may or may not include specific events experienced by individual subjects, but are developments within the research activity that suggest a potential for increased risks to subjects or others.

Adverse Event Grading/Classification Systems

All Adverse Events (AE) should be categorized or graded according to severity. Each protocol may have a unique approach to grading AEs, and the Principal Investigator should consult the master protocol and/or funding source for specific grading scales. Multi-center studies generally include such a table, sometimes called a “toxicity table” in the master protocol. A grading scale or toxicity table that will be used to grade AEs should be included in the Safety Monitoring Plan submitted.

It is strongly recommended that if a protocol does not already have a specific grading scale, the Common Terminology Criteria (CTCAE) scale be utilized. The CTCAE scale is available at ctep.cancer.gov.

An adverse event grading scale of mild-moderate-severe may be used for simple studies. A typical scale and definitions for these terms includes:

  • Mild Adverse Event – Event results in mild or transient discomfort, not requiring intervention or treatment; does not limit or interfere with daily activities (e.g., insomnia, mild headache).
  • Moderate Adverse Event – Event is sufficiently discomforting so as to limit or interfere with daily activities; may require interventional treatment (e.g., fever requiring antipyretic medication).
  • Severe and undesirable Adverse Event – Event results in significant symptoms that prevents normal daily activities; may require hospitalization or invasive intervention (e.g., anemia resulting in blood transfusion).
NOTE: Although not anticipated, adverse events may occur in any study and should be tracked (whether or not reportable) and graded by the investigator or study physician.
NC TraCS Institute logo vertical

In partnership with:

Contact Us


Brinkhous-Bullitt, 2nd floor
160 N. Medical Drive
Chapel Hill, NC 27599

919.966.6022
This email address is being protected from spambots. You need JavaScript enabled to view it.

Social


Cite Us


CitE and SUBMit CTSA Grant number - UM1TR004406

© 2008-2024 The North Carolina Translational and Clinical Sciences (NC TraCS) Institute at The University of North Carolina at Chapel Hill
The content of this website is solely the responsibility of the University of North Carolina at Chapel Hill and does not necessarily represent the official views of the NIH   accessibility | contact